Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saad Z Usmani

Showing results (1-10 of 253) with videos related to

Pageof 26
Sort By:
Oncotarget|September 20, 2012
Second primary malignancies and myeloma therapy: fad or fact?Saad Z Usmani
Clinical Lymphoma, Myeloma & Leukemia|February 8, 2024
SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMMEric Jurgens, Saad Z Usmani
Clinical Lymphoma, Myeloma & Leukemia|November 1, 2011
HSP90 inhibitors as therapy for multiple myelomaSaad Z Usmani, Gabriela Chiosis
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2014
Novel drug combinations for the management of relapsed/refractory multiple myelomaSaad Z Usmani, Sagar Lonial
Clinical Advances in Hematology & Oncology : H&O|September 28, 2016
The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapyPeter M Voorhees, Saad Z Usmani
Journal of Mammary Gland Biology and Neoplasia|August 11, 2006
Multifaceted role of Rho proteins in angiogenesisSofia D Merajver, Saad Z Usmani
Journal of the National Comprehensive Cancer Network : JNCCN|December 7, 2020
Defining and Managing High-Risk Multiple Myeloma: Current ConceptsLuciano J Costa, Saad Z Usmani
Blood Cancer Discovery|February 9, 2026
First-line Therapy in Newly Diagnosed Multiple MyelomaKevin C Miller, Saad Z Usmani
Current Hematologic Malignancy Reports|March 22, 2020
Extramedullary Disease in Multiple MyelomaMegan H Jagosky, Saad Z Usmani
Drugs|April 12, 2022
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma TherapyBarry Paul, Cesar Rodriguez, Saad Z Usmani
Pageof 26

Showing results (1-10 of 253) with videos related to

Sort By:
Pageof 26
Oncotarget|September 20, 2012
Second primary malignancies and myeloma therapy: fad or fact?Saad Z Usmani
Clinical Lymphoma, Myeloma & Leukemia|February 8, 2024
SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMMEric Jurgens, Saad Z Usmani
Clinical Lymphoma, Myeloma & Leukemia|November 1, 2011
HSP90 inhibitors as therapy for multiple myelomaSaad Z Usmani, Gabriela Chiosis
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2014
Novel drug combinations for the management of relapsed/refractory multiple myelomaSaad Z Usmani, Sagar Lonial
Clinical Advances in Hematology & Oncology : H&O|September 28, 2016
The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapyPeter M Voorhees, Saad Z Usmani
Journal of Mammary Gland Biology and Neoplasia|August 11, 2006
Multifaceted role of Rho proteins in angiogenesisSofia D Merajver, Saad Z Usmani
Journal of the National Comprehensive Cancer Network : JNCCN|December 7, 2020
Defining and Managing High-Risk Multiple Myeloma: Current ConceptsLuciano J Costa, Saad Z Usmani
Blood Cancer Discovery|February 9, 2026
First-line Therapy in Newly Diagnosed Multiple MyelomaKevin C Miller, Saad Z Usmani
Current Hematologic Malignancy Reports|March 22, 2020
Extramedullary Disease in Multiple MyelomaMegan H Jagosky, Saad Z Usmani
Drugs|April 12, 2022
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma TherapyBarry Paul, Cesar Rodriguez, Saad Z Usmani
Pageof 26